Genetics Genomics Pharma Companies Trials 
pharmaphorum
NOVEMBER 27, 2022
A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs. “It would have saved me and the NHS a lot of money. .” Why do we always have to follow? Why not lead?”
Drug Discovery World
JULY 19, 2023
Evan Floden , CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 28, 2022
Built under a government tender, AION Labs comprises four large international pharma companies – AstraZeneca , Merck, Pfizer , and Teva – and another core partner, the Israel Biotech Fund. Yerushalmi states there are numerous ways AI can support the pharma process – from clinical trials to patient stratification.
pharmaphorum
SEPTEMBER 7, 2022
Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The processes used are now seeing huge infrastructure commitments, in order to cement their place in the development of future products and trials. But our drug development processes are not perfect.
pharmaphorum
DECEMBER 6, 2022
A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. According to Genomics England , the project saw 18.5% Aims for the project. Hope for patients.
pharmaphorum
OCTOBER 18, 2022
US-based Tempus has built a precision medicine platform – powered by artificial intelligence and machine learning – that sifts through a large library of anonymised patient data, including results of clinical, molecular, and genomic testing.
XTalks
DECEMBER 20, 2023
This includes analyzing how drug combinations may impact individual patients or groups of patients before even entering a clinical trial. With a staggering 90 percent of drugs failing in clinical trials, AI has the potential to help improve these statistics. These companies are at various stages of research and clinical trials.
Expert insights. Personalized for you.
85 
Let's personalize your content